Olivia Quido Blemish Eraser

1.1Indication BLEMISH ERASER is a combination of hydrocortisone (a corticosteroid), hydroquinone (a melanin synthesis inhibitor), and a tretinoin (a retinoid) that is indicated for the gradual bleaching of hyperpigmented skin conditions age and liver spots, freckles, and other unwanted areas of melanin hyperpigmentation, in the presence of measures for sun avoidance, including the use of sunscreen.

1.2Limitations of Use

The safety and efficacy of BLEMISH ERASER in pregnant women and nursing mothers have not been established. BLEMISH ERASER is a hydroquinone (a melanin synthesis inhibitor) that is indicated for the gradual bleaching of hyperpigmented skin conditions age and liver spots, freckles, and other unwanted areas of melanin hyperpigmentation, in the presence of measures for sun avoidance, including the use of sunscreen. (1)

BLEMISH ERASER is contraindicated in individuals with a history of hypersensitivity to this product or any of its components.. (4) BLEMISH ERASER is contraindicated in individuals with a history of hypersensitivity to this product or any of its components.. (4)

5.1Hypersensitivity

If anaphylaxis, asthma or other clinically significantly hypersensitivity reactions occur, institute appropriate therapy and discontinue BLEMISH ERASER. Allergic contact dermatitis may also occur. Since this product contains no sunscreen, an effective broad spectrum sun blocking agent should be used and unnecessary solar exposure avoided, or protective clothing should be worn to cover bleached skin in order to prevent repigmentation from occurring.

5.2Exogenous Ochronosis BLEMISH

ERASER contains hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, the occurrence of which should prompt discontinuation of therapy. Most patients developing this condition are Black, but it may also occur in Caucasians and Hispanics. 5.3. Effects on Endocrine System Manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria can also be produced by systemic absorption of topical corticosteroid while treatment.